Our unique analytics are driving the next wave of precision medicine insights – finding new treatment opportunities for patients’ unmet medical needs in metabolic, inflammatory, respiratory, cardiovascular, women’s health, neurodegenerative and neuropsychiatric diseases
About usBetter understanding of complex disease biology
We believe that deciphering the complex combinatorial influences on disease biology in patient sub-groups is at the heart of successful drug programs
High-resolution stratification of populations and people
Accurately defining sub-groups of patients enables us to understand their disease risks and drivers, select the right patients for trials, and the right treatment for a patient
New disease insights through collaboration
We bring together data partners, charities, healthcare and life science companies, and Key Opinion Leaders to advance chronic disease outcomes
Why PrecisionLife?
Our unique combinatorial analytics platform unpicks the complex causes of disease and delivers a high-resolution patient stratification based on deep insights into novel target biology.
We bring together data, technology, industry experts and collaborative partners to transform our understanding of chronic disease and find new therapy options for patients.
PrecisionLife’s platform provides detailed contextual information on the SNPs, genes and pathways driving disease in patient sub-groups, and their active chemistry, tissue expression, mechanism of action, IP, clinical trials and more.
Pharma & Biotech
Selecting the right disease biology and drug target is crucial to innovative drug discovery
Clinical Development
Recruiting the right patients is critical to demonstrating efficacy and running smaller, faster and more successful clinical trials
Healthcare
Understanding the personal factors influencing chronic disease risk, progression rate and treatment response is vital to improved care
Latest Disease Studies
Read all Disease StudiesLatest News & Media
View all
News
Publications
Events
PrecisionLife and Sano Genetics announce partnership to accelerate understanding of long COVID and help identify new treatments
A new partnership between PrecisionLife and Sano Genetics will help advance researchers’ understanding of the drivers of long COVID,…
11/05/22
PrecisionLife announces appointment of Colin Stubberfield as SVP Drug Discovery to lead development of its precision medicine programs
PrecisionLife announces the appointment of Colin Stubberfield, Ph.D. as SVP Drug Discovery.
21/02/22
PrecisionLife announces first close of Series A financing to progress its drug discovery pipeline and commercial partnerships
OXFORD, UK January 31, 2022 – PrecisionLife announces the first close of its Series A investment round.
31/01/22
Value recognition in AI transactions
29 March 2022 – hosted by One Nucleus and Bristows PrecisionLife CEO and Co-founder, Dr Steve Gardner, will be…
21/03/22
Precision Medicine Outside of Oncology
29 March 2022 – part of the Precision Medicine Leaders Summit series PrecisionLife is sponsoring the Precision Medicine Leaders…
21/03/22
BIO Europe Spring 2022
28-31 March 2022 PrecisionLife is attending BIO Europe Spring from 28-31 March 2022. Delivered digitally, the event is expected…
21/03/22
Can AI Help Us Solve the Population Health Crisis?
PrecisionLife Co-founder and CEO, Steve Gardner, recently sat down with Inside Precision Medicine, the trade publication for molecular diagnostics…
4/03/22
Proving the Power of Combinatorial Analytics
Validation of COVID-19 Insights 70% of novel gene targets identified to be associated with serious disease and hospitalization with…
2/03/22
Supporting Women and Girls in Science
We hope to help support and inspire both young investigators and established female leaders in the field, especially on…
11/02/22